| Lundbeck (Schweiz) AG - Abilify Maintena 400 mg, Depot-Injektionssuspension |
| 63177 | | 02 | | Abilify Maintena 400 mg | | Depot-Injektionssuspension | | N05AX12 | | Aripiprazole | | 28.04.2014 | | |
|
| Composition |
| Praeparatio cryodesiccata: aripiprazolum 400 mg ut aripiprazolum monohydricum, carmellosum natricum, mannitolum, natrii dihydrogenophosphas monohydricus, natrii hydroxidum, pro vitro corresp. natrium max. 2.2 mg.
Solvens (i.m.): aqua ad iniectabile pro vitro.
Corresp. in solutione recenter reconstituta 200 mg pro 1 mL. |
| Packungsbestandteile |
| in solutione recenter reconstituta 200 mg pro 1 mL | | | |
| in solutione recenter reconstituta 200 mg pro 1 mL | | | |
| Praeparatio cryodesiccata: | | Depot-Injektionssuspension | | | | | | Active Agent | Dose |
|---|
| Aripiprazole | 400 mg |
| | | | Inactive agents |
|---|
| Carmellose Sodium | | Mannitol | | Sodium Dihydrogenophosphate Monohydrate | | Sodium Hydroxide |
|
|
| Package number | Package Size | EFP | CP | Category | SL | Out of trade (MedRef) |
|---|
| 004 | Durchstechflasche(n) à 400 mg | PR | PR | B | | Yes |
|
